{
    "clinical_study": {
        "@rank": "102589", 
        "acronym": "APERT", 
        "arm_group": {
            "arm_group_label": "Accelerated partial breast irradiation", 
            "arm_group_type": "Experimental", 
            "description": "Accelerated partial breast irradiation delivered by 3 dimensional conformal radiotherapy or intensity modulated radiotherapy"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine in a phase II clinical trial whether accelerated\n      partial breast irradiation after breast conserving surgery using 3 dimensional external beam\n      radiotherapy (3D-CRT) and intensity modulated radiotherapy (IMRT) for low-risk invasive\n      breast cancer patients is safe without causing serious late radiation side-effects."
        }, 
        "brief_title": "Accelerated Partial Breast Irradiation With 3D-CRT and IMRT", 
        "completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "Radiation Toxicity", 
            "Side Effects"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Radiation Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "It is a sequential phase II trial. Eligible patients after breast conserving surgery (BCS)\n      are treated with accelerated partial breast irradiation (APBI) using three-dimensional\n      conformal radiotherapy (3D-CRT) for the first 45 patients or intensity modulated\n      radiotherapy (IMRT) for the second 45 patients.\n\n      Primary end-point of the study: late radiation side-effects at 5 years. Early stopping\n      criteria: Not used as primary end-point is late side-effects. Interim analysis: Not planned\n      Secondary end-points: cosmetic results, quality of life, local recurrence-free survival,\n      regional recurrence free survival, distant metastasis free survival, relapse free survival,\n      overall survival, cancer specific survival.\n\n      Null-hypothesis for primary end-point: The incidence of severe (>G2) late radiation\n      side-effects after APBI using 3D-CRT or IMRT will not exceed 10%.\n\n      Stratification:\n\n        -  by treatment delivery: 3D-CRT - first 45 patients; IMRT - second 45 patients\n\n        -  by bra capsize: Capsize A-B; C; and D-D+\n\n      Treatment intervention: 9 x 4.1 Gy APBI using 3D-CRT (first 45 patients) or IMRT (second 45\n      patients) delivered within 5 days, using twice-a-day fractionation.\n\n      Clinical target volume (CTV) and Planning target volume (PTV) definition:\n\n      CTV = excision cavity + 20 mm minus the actual pathological surgical margin in mm PTV = CTV\n      + 5 mm in each direction\n\n      Follow-up:\n\n        -  ECOG PS, physical examination (inspection and palpation), registration of side-effects\n           (RTOG (Radiation Therapy Oncology Group) EORTC (European Organization for Research and\n           Treatment of Cancer)) early and late radiation morbidity scoring scheme) and cosmetic\n           results (using the Harvard scale) : 7-14 days after RT, than in every 3 months for 2\n           years, and every 6 months for 5 years.\n\n        -  Mammography: at 6, 12, 18, 24 months, and annually thereafter\n\n        -  Quality of life questionnaire (QLQ) (e.g. EORTC (European Organization for Research and\n           Treatment of Cancer) QLQ-30 and Breast (BR)-23) before RT, at 7-14 days after RT, at 3,\n           6, and 12 months, and annually thereafter\n\n        -  digital photography: before treatment, at 7-14 days after treatment, and yearly\n           thereafter"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  previous breast conserving surgery within 12 weeks (in case of adjuvant chemotherapy\n             within 28 days after completion of chemotherapy)\n\n          -  patient age > 40 years\n\n          -  ECOG performance status: 0-1\n\n          -  life expectancy >5 years\n\n          -  invasive ductal, papillary, mucinous, medullary or tubular carcinoma\n\n          -  unifocal tumor\n\n          -  pathological tumor size < or = 30 mm\n\n          -  pathological negative axillary nodal status with axillary dissection or sentinel\n             lymph node biopsy\n\n          -  surgical clips in the tumor bed\n\n          -  pathological surgical free margins of at least 2 mm\n\n          -  written informed consent of patients\n\n        Exclusion Criteria:\n\n          -  Stage III-IV\n\n          -  multifocal tumor\n\n          -  extensive intraductal component (EIC)\n\n          -  ductal or lobular carcinoma in situ (DCIS or LCIS)\n\n          -  invasive lobular cancer (ILC)\n\n          -  lymph-vascular invasion (LVI)\n\n          -  contralateral breast cancer\n\n          -  history of treatment for previous breast cancer\n\n          -  lactation or breast feeding women\n\n          -  Paget-disease of the nipple\n\n          -  psychiatric disorder\n\n          -  increased radiosensitivity (e.g. collagen vascular disease)"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02003560", 
            "org_study_id": "NIO-APERT_01"
        }, 
        "intervention": {
            "arm_group_label": "Accelerated partial breast irradiation", 
            "description": "9 x 4.1 Gy accelerated partial breast irradiation delivered by 3D-CRT or IMRT over 5 consecutive days, using twice-a-day fractionation.", 
            "intervention_name": "accelerated partial breast irradiation", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "breast cancer", 
            "breast conserving therapy", 
            "accelerated partial breast irradiation", 
            "3D conformal radiotherapy", 
            "intensity modulated radiotherapy"
        ], 
        "lastchanged_date": "December 6, 2013", 
        "location": {
            "contact": {
                "email": "polgar@oncol.hu", 
                "last_name": "Csaba Polg\u00e1r, MD, PhD, MSc", 
                "phone": "+36-1-2248690"
            }, 
            "facility": {
                "address": {
                    "city": "Budapest", 
                    "country": "Hungary", 
                    "zip": "H-1122"
                }, 
                "name": "National Institute of Oncology"
            }, 
            "investigator": [
                {
                    "last_name": "Csaba Polg\u00e1r, MD, PhD, MSc", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Norbert M\u00e9sz\u00e1ros, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Hungary"
        }, 
        "number_of_arms": "1", 
        "official_title": "Accelerated Partial Breast Irradiation After Breast Conserving Surgery for Low-risk Invasive Breast Cancer: 3D Conformal Radiotherapy (3D-CRT) and Intensity Modulated Radiotherapy (IMRT) - Prospective Phase II Study", 
        "other_outcome": {
            "description": "quality of life measured by the EORTC (European Organization for Research and Treatment of Cancer) QLQ-30 and BR-23 questionnaires", 
            "measure": "quality of life", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "overall_contact": {
            "email": "polgar@oncol.hu", 
            "last_name": "Csaba Polg\u00e1r, MD, PhD, MSc", 
            "phone": "+36-1-2248690"
        }, 
        "overall_official": [
            {
                "affiliation": "National Institute of Oncology", 
                "last_name": "Csaba Polg\u00e1r, MD, PhD, MSc", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "National Institute of Oncology", 
                "last_name": "Norbert M\u00e9sz\u00e1ros, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Hungary: Scientific and Medical Research Council Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Late radiation side-effects at 5 years scored by the RTOG (Radiation Therapy Oncology Group) EORTC (European Organization for Research and Treatment of Cancer) late radiation morbidity scoring scheme", 
            "measure": "late radiation side-effect", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02003560"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Institute of Oncology, Hungary", 
            "investigator_full_name": "Csaba Polg\u00e1r", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "cosmetic results at 5 years measured by the Harvard criteria", 
                "measure": "cosmetic results", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Local tumor control defined as reappearance of the tumor in the ipsilateral breast", 
                "measure": "local tumor control", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "regional tumor control at 5 years", 
                "measure": "regional tumor control", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "overall survival at 5 years", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "disease free survival at 5 years", 
                "measure": "disease free survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "cancer specific survival at 5 years", 
                "measure": "cancer specific survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }
        ], 
        "source": "National Institute of Oncology, Hungary", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Oncology, Hungary", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2006", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}